Tecarfarin clinical trials
Also written ATI-5923.
How each study uses tecarfarin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2018 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Lee's Pharmaceutical Limited (2) · ARYx Therapeutics (2) · Espero Biopharma (1)
Studies
Open first, then newest update. How each study uses tecarfarin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese VolunteersStatus unknownPhase 1Lee's Pharmaceutical LimitedNCT04627116Written as TecarfarinHow we know
- A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese VolunteersCompletedPhase 1Lee's Pharmaceutical LimitedNCT03652779Written as Tecarfarin 10mgHow we know
- Tecarfarin Anti-Coagulation Trial (TACT)Status unknownPhase 3Espero BiopharmaNCT02522221Written as tecarfarinHow we know
- Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic AnticoagulationStatus unknownPhase 2/3ARYx TherapeuticsNCT00691470Written as ATI-5923How we know
- Study of a New Anticoagulant Drug in Patients With Atrial FibrillationCompletedPhase 2ARYx TherapeuticsNCT00431782Written as ATI-5923How we know
Codes
What other systems call tecarfarin · ClinicalTrials.gg INT005573
- MeSH (NLM) C547288tecarfarinOne source NLM
- UNII (FDA) WN1479YT50TECARFARINConfirmed FDA, NLM, Wikidata
- Wikidata Q27292724tecarfarinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152523TecarfarinOne source FDA
- DrugBank DB12823One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547288 | tecarfarin | One source NLM |
| UNII (FDA) | WN1479YT50 | TECARFARIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27292724 | tecarfarin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152523 | Tecarfarin | One source FDA |
| DrugBank | DB12823 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.